Acurx Pharmaceuticals, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Acurx Pharmaceuticals, Inc. (ACXP) reported Cash and Cash Equivalents, Period Increase (Decrease) of $9.78 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-16.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2022-03-16
- Acurx Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-12-31 was -$1.50M.
- Acurx Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-09-30 was -$2.64M, a 284.09% decline year-over-year.
- Acurx Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-12-31 was -$231.22K.
- Acurx Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-09-30 was $1.43M.
- Acurx Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2021 was $9.78M, a 1313.61% increase from fiscal 2020.
- Acurx Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2020 was $692.09K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | -$4.14M derived: sum of 2 quarters · filed 2022-03-16 | $9.78M 10-K · filed 2022-03-16 | |
| 2021-09-30 | -$2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $11.28M 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | $13.92M 10-Q · filed 2021-08-13 | |||
| 2020-12-31 | -$231.22K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $1.20M derived: sum of 2 quarters · filed 2022-03-16 | $692.09K 10-K · filed 2022-03-16 | |
| 2020-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $923.31K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | -$508.88K 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |